4//SEC Filing
INFINITY PHARMACEUTICALS, INC. 4
Accession 0001181431-06-052817
CIK 0001113148operating
Filed
Sep 12, 8:00 PM ET
Accepted
Sep 13, 7:59 PM ET
Size
14.4 KB
Accession
0001181431-06-052817
Insider Transaction Report
Form 4
LANDER ERIC S
Director
Transactions
- Award
Common Stock
2006-09-12+61,887→ 61,887 total - Award
Common Stock
2006-09-12+9,818→ 9,818 total - Award
Stock Option (right to buy)
2006-09-12+28,125→ 28,125 totalExercise: $15.04Exp: 2016-09-12→ Common Stock (28,125 underlying) - Award
Stock Option (right to buy)
2006-09-12+2,210→ 2,210 totalExercise: $3.48Exp: 2016-06-12→ Common Stock (2,210 underlying)
Footnotes (9)
- [F1]Reflects a 1-for-4 reverse stock split, which became effective on September 12, 2006.
- [F2]Received in exchange for 280,000 shares of Infinity Discovery, Inc. ("IPI") common stock in connection with the merger of IPI into Infinity Pharmaceuticals, Inc. (the "Merger") based on a conversion ratio of 0.88411.
- [F3]Received in exchange for 50,000 shares of IPI Series A Preferred Stock in connection with the Merger based on a conversion ratio of 0.78550. The Series A Preferred Stock had no expiration date.
- [F4]Received in exchange for 280,000 shares of IPI common stock in connection with the Merger based on a conversion ratio of 0.88411.
- [F5]The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F6]The option vests as to 9,375 of the shares on the first anniversary of the grant date, which grant date was September 12, 2006, and the remainder in quarterly installments of 2,343 shares beginning at the end of the first quarter thereafter, provided that the holder continues to serve as a director.
- [F7]The option vests as to 552 shares on June 12, 2006, 184 shares on June 30, 2006 and the remainder in equal monthly installments through February 2007.
- [F8]Received in the Merger in exchange for a stock option to acquire 10,000 shares of IPI common stock for $0.77 per share based on a conversion ratio of 0.88411.
- [F9]The exercise price reflects the exercise price of each option to purchase IPI common stock prior to the closing of the Merger divided by a conversion ratio of 0.88411, as adjusted to reflect the 1-for-4 reverse stock split.
Documents
Issuer
INFINITY PHARMACEUTICALS, INC.
CIK 0001113148
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001113148
Filing Metadata
- Form type
- 4
- Filed
- Sep 12, 8:00 PM ET
- Accepted
- Sep 13, 7:59 PM ET
- Size
- 14.4 KB